Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
26.89
+1.23 (4.79%)
At close: Aug 13, 2025, 4:00 PM
26.93
+0.04 (0.15%)
After-hours: Aug 13, 2025, 7:59 PM EDT
Moderna Revenue
Moderna had revenue of $142.00M in the quarter ending June 30, 2025, a decrease of -41.08%. This brings the company's revenue in the last twelve months to $3.08B, down -39.05% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$3.08B
Revenue Growth
-39.05%
P/S Ratio
3.37
Revenue / Employee
$530,690
Employees
5,800
Market Cap
10.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MRNA News
- 2 days ago - FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Benzinga
- 7 days ago - Moderna's stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals - Market Watch
- 9 days ago - Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish - Seeking Alpha
- 12 days ago - Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent - Fast Company
- 12 days ago - Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay - Investopedia
- 12 days ago - Moderna cuts 2025 revenue to $2.2B after UK booster delay - Invezz
- 12 days ago - Moderna is laying off 10% of its workforce. Does RFK Jr. have anything to do with it? - Fast Company